PARP1 and Familial prostate cancer: This case is consistent with recent reports of BRCA reversions in both germline and somatic alterations reported in prostate cancer, ovarian cancer, and breast cancer after treatment with PARP inhibitors, which were associated with resistance to treatment20–22,24,25.